Introduction
============

The most common endocrine malignancy is thyroid cancer. Papillary and follicular thyroid carcinoma are the most frequent subtypes. Metastatic thyroid carcinoma usually appears in the local lymph nodes. Indeed, distant metastases of papillary and follicular thyroid carcinoma are uncommon. When these occur, the sites typically include lung and bone. However, albeit rare, papillary and follicular thyroid carcinoma have both been associated with skin metastases \[[@b1-dp0504a03],[@b2-dp0504a03]\].

Cutaneous metastases from papillary thyroid carcinoma are reported in less than 1 in 1,000 patients with this cancer \[[@b2-dp0504a03]\]. The scalp is the most frequent site \[[@b3-dp0504a03]--[@b7-dp0504a03]\]. A man with progressing metastatic papillary thyroid cancer to lung who developed a cutaneous metastasis on the nose mimicking a basal cell carcinoma is described and the various clinical presentations of metastatic papillary thyroid cancer to skin are reviewed.

Case report
===========

A 72-year-old man was referred by his oncologist for evaluation of a lesion on his nose that was suspected to be a basal cell carcinoma. The lesion was painless and had appeared 3 weeks earlier.

His past medical history was significant for metastatic papillary thyroid carcinoma diagnosed 6.5 years earlier. A total thyroidectomy and neck dissection was followed by adjuvant radioactive iodine-131. When lung nodules were discovered 1.25 years later, he received another treatment with iodine-131. He subsequently developed progressive chest disease 0.75 years later and received an additional treatment of iodine-131 in combination with capecitabine. He received stereotactic radiosurgery to lung metastases 1 year later; 2 years and 3.3 years later, he had excision of enlarged chest lymph nodes that showed tumor.

Restaging, 3 months prior to his nose lesion, showed not only intrathoracic metastatic disease (with pulmonary nodules and enlarged mediastinal lymph nodes), but also metastases to the right adrenal gland and bone. He was experiencing progressive fatigue. However, there was neither cough nor difficulty breathing.

Cutaneous examination showed an asymptomatic 7 × 7 mm violaceous non-telangiectatic nodule with central erosion on the right nasal tip ([Figure 1](#f1-dp0504a03){ref-type="fig"}). Microscopic examination of a 2 mm punch showed scale crust and parakeratosis overlying an atrophic epidermis. In the dermis, there were multiple nodules composed of large cells forming papillary projections. The papillae were composed of a stratified lining of cuboidal and columnar tumor cells with eosinophilic cytoplasm and a central fibrovascular core that contained occasional lymphocytes. Focally, there were tumor cells with altered nuclear morphology. Some cells showed crowding and overlapping of enlarged and elongated nuclei. Other cells demonstrated intranuclear cytoplasmic pseudoinclusions ([Figure 2](#f2-dp0504a03){ref-type="fig"}). The tumor cells stained positive for thyroid transcription factor-1 (TTF-1) and paired box gene 8 (PAX8).

Correlation of the clinical history and pathology established a diagnosis of metastatic papillary thyroid carcinoma to skin. The residual tumor on the nose was excised without recurrence. However, within 6 months, he had progressive shortness of breath; follow up studies showed progressive chest disease.

His tumor was sent for genomic studies (Foundation One, Cambridge, MA). An aberration in the rearranged during transfection (RET) receptor tyrosine kinase was identified: an in-frame fusion of coiled-coil domain containing 6 (CCDC6) up to intron 1, with RET from intron 11 to the end. Treatment was initiated and maintained with the RET inhibitor vandetanib; he has had stable metastatic disease without symptoms 1.5 years after starting this drug.

Discussion
==========

Cutaneous metastases may develop in patients with an established diagnosis of cancer. In this setting, they typically herald the onset of either relapsing or progressive disease in an oncology patient. However---albeit less commonly---they can be the initial presentation of an unsuspected internal malignancy in a previously cancer-free individual.

The morphology of cutaneous metastases is variable. The lesions can present as patches, plaques, papules or nodules. They can mimic other conditions such as alopecia, infections (erysipelas and paronychia), benign cysts (epidermoid or pilar), pyogenic granuloma and cutaneous malignant neoplasms (basal cell carcinoma and keratoacanthoma) \[[@b4-dp0504a03],[@b5-dp0504a03],[@b7-dp0504a03]\].

Common skin manifestations of metastatic papillary thyroid cancer, in addition to scalp nodules, include neck nodules \[[@b3-dp0504a03],[@b4-dp0504a03],[@b8-dp0504a03]\] and lesions on the thyroidectomy scar \[[@b1-dp0504a03]\]. Metastatic tumor at the fine-needle aspiration biopsy site has been observed \[[@b8-dp0504a03]\]. Also, lesions of cutaneous papillary thyroid carcinoma metastases have been described on the abdominal wall \[[@b6-dp0504a03],[@b9-dp0504a03]\], arm \[[@b6-dp0504a03]\], buttock \[[@b9-dp0504a03]\], chest wall \[[@b3-dp0504a03]\], face \[[@b3-dp0504a03],[@b6-dp0504a03]\], shoulder \[[@b6-dp0504a03]\] and thigh \[[@b9-dp0504a03]\].

Microscopic examination of papillary thyroid carcinoma cutaneous metastases shows similar pathology features as the primary cancer. Immunohistochemical stains can also be helpful to confirm the diagnosis and exclude tumors originating from other organs. Papillary thyroid carcinoma typically expresses thyroid transcription factor-1 (TTF-1, a 38-kd homeodomain containing DNA binding nuclear protein expressed in the follicular cells of the thyroid and present in 93% of thyroid tumors) \[[@b4-dp0504a03],[@b10-dp0504a03]\] and thyroglobulin (a 670-kd glycoprotein synthesized in the cytoplasm of follicular thyroid epithelial cells and detected in 95% of papillary thyroid carcinomas) \[[@b3-dp0504a03],[@b4-dp0504a03]\]. It also usually expresses cytokeratin 7 (a type II keratin found in the follicular cells of the thyroid gland) \[[@b11-dp0504a03]\] and paired box gene 8 (PAX8, a nephric-lineage transcription factor that is a crucial transcription factor for the organogenesis of the kidney, the Mullerian system and the thyroid gland) \[[@b12-dp0504a03]\].

The nose is an unusual site for cutaneous metastases. In addition to thyroid carcinoma, other cancers with metastatic lesions on the nose include solid tumors originating from the breast, cervix, liver, lung and testes \[[@b13-dp0504a03]\]; immunohistochemical markers can be used to differentiate the organ of origin of these metastatic tumors ([Table 1](#t1-dp0504a03){ref-type="table"}). The described patient was referred for evaluation of a suspected basal cell carcinoma. Morphologic features of the nodule that suggested the possibility of metastatic tumor included its violaceous appearance and the absence of telangiectasias.

In addition to the patient in this report, another man with papillary thyroid carcinoma also had a cutaneous metastasis on his nose; in this individual, the nose lesion was the initial presentation of his metastatic disease \[[@b14-dp0504a03]\]. He was a 73-year-old Caucasian man who developed a raised, non-pigmented lesion on his left nasal ridge; biopsy revealed papillary thyroid carcinoma. In addition to a thyroid mass, he had metastases to his lungs, bone and liver. Management included a partial thyroidectomy, palliative radiotherapy (to the neck and cervical spine to treat tracheal invasion of the tumor and spinal cord compression, respectively), doxorubicin and radioactive iodine. Three years later, his lung and pleural lesions progressed; pathology demonstrated anaplastic transformation of his tumor \[[@b14-dp0504a03]\].

Similar to the reported patient, other investigators have commented that since " . . . the natural history of thyroid cancer is one of slow progression skin metastases may be confused with other skin neoplasms such as basal cell carcinoma . . ." \[[@b5-dp0504a03]\] Indeed, their patient---a 70-year-old man---presented with a enlarged thyroid gland and cervical lymphadenopathy; pathology from his total thyroidectomy and neck dissection established a diagnosis of papillary thyroid carcinoma. Three years after receiving adjuvant treatment with radioactive iodine ablation and external beam radiotherapy, he developed a 1 cm nodular scalp lesion that was clinically thought to be a basal cell carcinoma; however, excisional biopsy showed papillary thyroid carcinoma. Within four months, he died \[[@b5-dp0504a03]\].

Cutaneous metastasis of papillary thyroid carcinoma may be the presenting manifestation of previously undiagnosed malignancy \[[@b3-dp0504a03],[@b14-dp0504a03]\]. The described patient's nose lesion of metastatic papillary thyroid carcinoma occurred 6.5 years following his initial diagnosis of cancer and in the setting of progressive metastatic disease that had been treated with iodine-131 (on three occasions, without or with concurrent capecitabine) and stereotactic radiosurgery. Similar to this patient, many of the individuals who develop skin metastases from papillary thyroid carcinoma typically present with cutaneous lesions several years (ranging from less than 2 years to 20 years) following the diagnosis of their original cancer \[[@b1-dp0504a03],[@b3-dp0504a03],[@b4-dp0504a03],[@b6-dp0504a03]--[@b8-dp0504a03]\].

The prognosis for patients with metastatic papillary thyroid carcinoma to the skin, in general, is unfavorable \[[@b3-dp0504a03],[@b5-dp0504a03]\]. However, there are several individuals with metastatic papillary thyroid carcinoma who survive several years after diagnosis with indolent disease \[[@b1-dp0504a03],[@b3-dp0504a03],[@b9-dp0504a03]\]. Also, similar to the described patient, with the advent of molecular targeted therapies, such as tyrosine kinase inhibitors, the prognosis for patients with metastatic disease---and particularly those with rearranged during transfection (RET) proto-oncogene aberrations---is better than that observed in individuals with papillary thyroid carcinoma who were treated prior to the discovery of these agents \[[@b15-dp0504a03]\].

Conclusion
==========

Papillary thyroid carcinoma with skin metastases is rare. Cutaneous metastases of papillary thyroid carcinoma most commonly occur as nodules on the scalp, neck, and thyroidectomy scars. A man with progressive metastatic papillary thyroid carcinoma developed a cutaneous metastasis on his nose; the lesion morphologically mimicked a basal cell carcinoma. Cutaneous papillary thyroid carcinoma metastases may not only occur several years following the diagnosis of the primary cancer, but also can occur on the nose or mimic basal cell carcinoma or both. Cutaneous metastases of papillary thyroid carcinoma have previously been associated with a poor prognosis; however, some of the patients have indolent neoplastic disease and survive for several years. Similar to the described patient, whose genomic evaluation of the tumor showed an aberration involving the rearranged during transfection (RET) receptor tyrosine kinase, the use of molecular targeted therapies may provide extended survival for individuals diagnosed with cutaneous metastatic papillary thyroid carcinoma.
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###### 

Lateral **(a)** and upward **(b)** views of cutaneous metastatic papillary thyroid carcinoma presenting as an asymptomatic nodule with central erosion on the right nasal tip that morphologically mimicked a basal cell carcinoma. \[Copyright: ©2015 Cohen.\]
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###### 

Low **(a)**, medium **(b)**, and high **(c)** magnification views of the papillary thyroid carcinoma metastasis shows aggregates of tumor cells in the dermis that are similar to those of the primary thyroid neoplasm. Cuboidal and columnar cells line the lymphocyte-containing fibrovascular cores of tumor papillae. The cells have eosinophilic cytoplasm; some of them also have nuclear changes including enlarged and enlongated nuclei that are crowded and overlapping and nuclear pseudoinclusions \[hematoxylin and eosin; a = ×10, b = ×20, c = ×40\]. \[Copyright: ©2015 Cohen.\]
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###### 

Immunohistochemistry markers of solid tumors that metastasize to the nose

  **Tumor origin**   **Immunohistochemical marker**
  ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Breast             ER (estrogen receptor)GATA3 (GATA binding protein 3)GCDFP-15 (gross cystic protein fluid protein 15)HER2 (human epithelial growth factor 2)MGB (mammaglobin)NY-BR-1 (ankyrin repeat domain 30A)PR (progesterone receptor)TFF1 (thyroid transcription factor 1)TFF3 (thyroid transcription factor 3)
                     
  Cervix             Ca-125 (cancer antigen 125)CEA (carcinoembryonic antigen)Cytokeratin 17Human papilloma virusMYBL2 (myeloblastosis family transcription factor-like 2)P16 (p16INK4a = cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1)
                     
  Liver              ARG1 (arginase 1)CD10 (cluster of differentiation 10)CD34 (cluster of differentiation 34)HepPar1 (hepatocyte paraffin 1)GPC3 (glypican 3)
                     
  Lung               
  NSCLC              Cytokeratin AE1/AE3 (pan-cytokeratin)CAM5.2 (Cytokeratin 8 and cytokeratin 18)Desmocollin AGenomic aberrations Alk (anaplastic lymphoma kinase) rearrangementEGFR (epidermal growth factor receptor) mutationHMWK (high molecular weight cytokeratin) Cytokeratin 5/6Cytokeratin 34betaE12Napsin-Ap63 (p53 family of nuclear transcription factors)TTF1 (thyroid transcription factor 1)Cytokeratin AE1/AE3 (pan-cytokeratin)
  SCLC               Neuroendocrine markers CD56 (cluster of differentiation 56 = NCAM, neural cell adhesion molecule)ChromograninSynaptophysin
                     
  Testes             
  GCT                Cytokeratin AE1/AE3 (pan-cytokeratin)NanogOCT4 (octomer-binding transcription factor 4)PLAP (placenta-like alkaline phosphatase)SALL4 (sal-like 4)Calret (calretinin)
  SC/ST              INHA (inhibin A)Vlm (vimentin)
                     
  Thyroid            BRAF (B-isoform of RAF kinase) V600E mutation-specific antibodies Anti-B-Raf mouse monoclonal antibodyVE1CIT-ED1 (Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain, 1)Cytokeratin 7Cytokeratin 19GAL-3 (galectin-3)HBME-1 (Hector Battifora mesothelioma-1)PAX8 (paired box gene 8)ThyroglobinTPO (thyroperoxidase)TROP2 (trophoblastic cell surface antigen 2 = TAC-STD2, tumor associated calcium signal transducer 2)TTF1 (thyroid transcription factor 1)TTF2 (thyroid transcription factor 2 = FOXE1, forkbend box E1)

Abbreviations: GCT, germ cell tumor; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SC/ST, sex cord/stromal tumor.
